Psychiatric Context and Home-Use Claims for Neuromodulation

Urgent guidance first

If you or someone you know is thinking about suicide or is in emotional crisis, call or text 988 (the 988 Suicide & Crisis Lifeline, US) or call 911 if there is immediate danger.[1] A stimulation device is not a crisis tool. If mood gets worse, or unusual energy, very little need for sleep or racing thoughts appear, contact a clinician promptly.

This page is information only. It does not tell anyone to start, stop or change a treatment or medicine, and it gives no device settings.

Where the evidence stands, by use

"Proper evidence not found" means I looked at the FDA records and the reviews above and did not find product-level evidence for that use. It does not prove there is no effect.

What the home-use approval actually showed

In the pivotal Empower trial summarized by the FDA, 173 adults were analyzed (87 active, 86 sham). On the main depression scale the average change was -9.4 with active stimulation and -7.1 with sham, a 2.3-point difference. Response rates were 54.4 percent and 26.9 percent.[6] These are scale scores and group averages, not a promise for any one person. The FDA described moderate uncertainty about the benefit because participants could tell which treatment they had (unblinding), no clinically significant change was prespecified, and the literature conflicted.[6]

Common side effects were skin redness (63.5 percent active versus 18.5 percent sham) and itching, burning, headache and scalp pain. One serious adverse event, hypertension, occurred in the active group and none were attributed to the device. The trial excluded mania, psychosis, seizure history and certain suicide-risk histories, and the FDA listed mania or hypomania as a potential effect based on other tDCS literature.[6]

Why psychiatric history changes the picture

• Mania risk. An international safety review reported very rare mania or hypomania in people with depression receiving tDCS (11 documented cases), though cause is hard to prove.[7]
• Bipolar disorder. Evidence is more limited than for unipolar depression, as the table shows.

Reading home-use claims

1. A claim of "treats depression" for a product with no FDA record is a marketing claim.
2. Approval for MDD does not extend to anxiety, ADHD, insomnia, PTSD or "brain optimization."
3. A prescription device should come with a clinician who screens and follows up.
4. Ask whether the study used the exact product you are being sold.

For regulatory detail see device-specific approval for brain stimulation. For evidence by technique see neuromodulation for depression. Practical mood guidance sits in stress, anxiety, burnout and depression.